Quadrature Capital Ltd Makes New $281,000 Investment in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Quadrature Capital Ltd acquired a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the third quarter, Holdings Channel.com reports. The fund acquired 3,020 shares of the medical instruments supplier’s stock, valued at approximately $281,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of LMAT. Verition Fund Management LLC purchased a new stake in shares of LeMaitre Vascular in the 3rd quarter valued at approximately $415,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in LeMaitre Vascular by 98.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,129 shares of the medical instruments supplier’s stock worth $569,000 after acquiring an additional 3,036 shares during the period. Glenmede Trust Co. NA increased its stake in LeMaitre Vascular by 1.3% during the third quarter. Glenmede Trust Co. NA now owns 10,512 shares of the medical instruments supplier’s stock worth $976,000 after acquiring an additional 136 shares during the last quarter. Townsquare Capital LLC raised its position in LeMaitre Vascular by 38.0% in the third quarter. Townsquare Capital LLC now owns 47,953 shares of the medical instruments supplier’s stock valued at $4,454,000 after purchasing an additional 13,210 shares during the period. Finally, BNP Paribas Financial Markets lifted its stake in shares of LeMaitre Vascular by 80.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 27,829 shares of the medical instruments supplier’s stock valued at $2,585,000 after purchasing an additional 12,432 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on LMAT. Oppenheimer reissued an “outperform” rating and set a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Barrington Research lifted their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. StockNews.com raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Thursday, December 5th. Cantor Fitzgerald started coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 target price for the company. Finally, JMP Securities increased their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 20th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, LeMaitre Vascular has a consensus rating of “Moderate Buy” and an average target price of $94.57.

LeMaitre Vascular Stock Performance

Shares of LMAT opened at $99.40 on Wednesday. The stock has a 50-day simple moving average of $97.08 and a 200-day simple moving average of $89.17. LeMaitre Vascular, Inc. has a 1 year low of $52.72 and a 1 year high of $109.58. The stock has a market capitalization of $2.23 billion, a PE ratio of 54.32, a PEG ratio of 2.48 and a beta of 0.93.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. During the same quarter in the previous year, the firm earned $0.33 earnings per share. The firm’s quarterly revenue was up 15.6% on a year-over-year basis. Analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 5th. Investors of record on Thursday, November 21st were issued a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.64%. The ex-dividend date of this dividend was Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 34.97%.

Insider Buying and Selling at LeMaitre Vascular

In other news, Director Bridget A. Ross sold 3,750 shares of the stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the transaction, the director now owns 2,278 shares in the company, valued at approximately $231,148.66. This represents a 62.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 10.79% of the stock is owned by insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.